RJA
PTGX icon

Raymond James & Associates’s Protagonist Therapeutics PTGX Stock Holding History

Raymond James & Associates’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$605K Buy
13,455
+2,926
+28% +$118K ﹤0.01% 2998
2024
Q2 		$365K Sell
10,529
-422
-4% -$12.4K ﹤0.01% 3259
2024
Q1 		$317K Buy
+10,951
New +$298K ﹤0.01% 3346

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's PTGX Position: Q3 2024 in Review

Raymond James & Associates increased its Protagonist Therapeutics (PTGX) stake by 28% in Q3 2024, buying an estimated $118K and bringing the position to 13,455 shares worth $605K. The position accounts for ﹤0.01% of the portfolio, ranked #2998.

Raymond James & Associates first reported a position in PTGX in Q1 2024 and has held it in 3 quarters since. 240 funds tracked by Wall St. Rank hold PTGX as of Q3 2024.

  • Raymond James & Associates held 13,455 shares of Protagonist Therapeutics worth $605K as of Q3 2024.
  • Raymond James & Associates bought 2,926 Protagonist Therapeutics shares in Q3 2024, an estimated $118K.
  • Protagonist Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2998 holding.
  • Raymond James & Associates first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 240 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.